meniscal pain of degenerative origin
Conditions
Brief summary
The primary endpoint is the change in meniscal pain measured using the Visual Analog Scale (VAS) between the initial visit and the 1-month follow-up visit
Detailed description
the evolution of the VAS score between the initial visit and the 3-month follow-up visit, the evolution of the score of each dimension (Pain, Symptoms, Activities of daily living, Sport and recreation function, and Knee-related qualities of life) of the algo-functional scale KOOS (appendix 1) between the initial visit and the 1-month follow-up visit, the evolution of each dimension of the algo-functional scale KOOS score between the initial visit and the 3-month follow-up visit, the occurrence of adverse events (AEs) and serious AEs (SAEs) up to 3 months of follow-up, Analgesic response is defined as a at least 50% reduction in pain (measured using the VAS scale) between the initial visit and the 1-month follow-up visit.
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the change in meniscal pain measured using the Visual Analog Scale (VAS) between the initial visit and the 1-month follow-up visit | — |
Secondary
| Measure | Time frame |
|---|---|
| the evolution of the VAS score between the initial visit and the 3-month follow-up visit, the evolution of the score of each dimension (Pain, Symptoms, Activities of daily living, Sport and recreation function, and Knee-related qualities of life) of the algo-functional scale KOOS (appendix 1) between the initial visit and the 1-month follow-up visit, the evolution of each dimension of the algo-functional scale KOOS score between the initial visit and the 3-month follow-up visit, the occurrence of adverse events (AEs) and serious AEs (SAEs) up to 3 months of follow-up, Analgesic response is defined as a at least 50% reduction in pain (measured using the VAS scale) between the initial visit and the 1-month follow-up visit. | — |
Countries
France